Nutex Health (NASDAQ:NUTX) Trading Down 7.3% – Time to Sell?

Nutex Health Inc. (NASDAQ:NUTX)’s share price was down 7.3% on Tuesday . The stock traded as low as $162.39 and last traded at $162.9050. Approximately 46,216 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 151,923 shares. The stock had previously closed at $175.78.

Analysts Set New Price Targets

Several analysts have issued reports on NUTX shares. Wall Street Zen upgraded Nutex Health from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 28th. Maxim Group set a $205.00 price target on Nutex Health and gave the company a “buy” rating in a research report on Tuesday, August 26th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Nutex Health in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $252.50.

Nutex Health Trading Up 4.9%

The firm has a market cap of $1.18 billion, a P/E ratio of 9.02 and a beta of -0.03. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.18 and a current ratio of 3.20. The firm has a fifty day moving average of $129.44 and a 200-day moving average of $113.26.

Nutex Health (NASDAQ:NUTX) last issued its earnings results on Tuesday, November 18th. The company reported $7.76 earnings per share for the quarter, topping the consensus estimate of ($5.43) by $13.19. Nutex Health had a return on equity of 37.44% and a net margin of 11.62%.The firm had revenue of $243.99 million for the quarter, compared to analyst estimates of $221.93 million.

Insider Transactions at Nutex Health

In other news, CFO Jon Christian Bates bought 750 shares of Nutex Health stock in a transaction on Tuesday, November 25th. The stock was purchased at an average cost of $136.71 per share, with a total value of $102,532.50. Following the purchase, the chief financial officer directly owned 5,638 shares of the company’s stock, valued at approximately $770,770.98. This trade represents a 15.34% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 36.92% of the stock is owned by insiders.

Institutional Trading of Nutex Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pertento Partners LLP bought a new position in shares of Nutex Health in the third quarter valued at approximately $27,940,000. Topline Capital Management LLC lifted its position in Nutex Health by 80.0% in the third quarter. Topline Capital Management LLC now owns 556,567 shares of the company’s stock worth $57,505,000 after purchasing an additional 247,436 shares during the period. Marshall Wace LLP boosted its stake in Nutex Health by 333.4% during the 2nd quarter. Marshall Wace LLP now owns 94,548 shares of the company’s stock valued at $11,770,000 after purchasing an additional 72,734 shares in the last quarter. Millennium Management LLC boosted its stake in Nutex Health by 191.1% during the 3rd quarter. Millennium Management LLC now owns 93,396 shares of the company’s stock valued at $9,650,000 after purchasing an additional 61,308 shares in the last quarter. Finally, Divisadero Street Capital Management LP acquired a new position in shares of Nutex Health during the 2nd quarter valued at $7,481,000. 5.32% of the stock is currently owned by institutional investors.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.